key: cord-0993631-nywz0h6q authors: Sidiq, Zeeshan; Hanif, M.; Dwivedi, Kaushal Kumar; Chopra, K.K. title: Laboratory diagnosis of Novel corona virus (2019-nCoV)-present and the future date: 2020-10-01 journal: Indian J Tuberc DOI: 10.1016/j.ijtb.2020.09.023 sha: d52362514fe52990e43a3bfb77b70dfc9bd52242 doc_id: 993631 cord_uid: nywz0h6q In December 2019 a novel coronavirus SARS-CoV-2 emerged in the Hunan seafood market in Wuhan, China, and soon became a global health problem. Since its outbreak, SARS-CoV-2 has had a major impact on clinical diagnostic laboratories. The scientific community has quickly risen to the occasion and reports of new developments have arrived at an unprecedented scale. At present, there is a growing list of over 400 SARC-CoV-2 diagnostic tests either in development or approved for clinical use. This presentation reviews the current laboratory methods available for testing COVID- 19 in microbiology laboratories and also provides an insight into the future diagnostics approaches. Proper respiratory specimen collected at the appropriate time and from the right anatomical site is critical in the accurate and timely diagnosis of SARSCoV2. While oropharyngeal and nasopharyngeal swabs are recommended for the detection of early infection, other lower respiratory tract specimens like the sputum and bronchoalveolar lavage are used for late detection and monitoring of patients with severe COVID-19 pneumonia. Real-time RT-PCR based molecular assay remains the test of choice for the etiological diagnosis of SARS-CoV-2 while serological tests are being introduced as supplementary tools. Finally, there is an urgent need for scaling up the diagnostic capacity by the introduction of reliable and accurate point-of-care tests which will assist in effective control of this outbreak. These assays can be used in the local hospitals and clinics bearing the burden of identifying and treating patients. Coronaviruses belong to family Coronaviridae which include four genera designated by Greek letters alpha, beta, delta, and gamma 1 March 12th, 2020, WHO declared the 2019-nCoV outbreak as pandemic 5 . The spectrum of this disease in humans is yet to be fully determined. The incubation period of SARS-CoV-2 infection is almost similar to that of SARS. The reported mean incubation period of the disease is 5.2 days 6 . The reported symptoms include fever and cough reported early in the course of illness 7, 8 . Infections are also characterized by dyspnoea, respiratory distress, and a positive chest X-ray 9 . Lower respiratory symptoms often develop about 1 week from the onset of initial symptoms 7 . As of August 16, 2020, a total 21,294,845 confirmed cases and 761,779 deaths due to 2019-nCoV have been reported globally 10 . There is thus an urgent need for reliable diagnostic tests specific for confirming suspected cases, screening patients, and conducting virus surveillance. Upper respiratory tract specimens collected within 5-6 days of the onset of the symptoms have demonstrated high viral loads. Thus, a nasopharyngeal and/or an oropharyngeal swab are recommended for initial screening and diagnosis of early infection 11, 12 . Swabs should have flocked nontoxic synthetic fibers, such as polyester, as well as synthetic nylon handles 13 . Because of its safety and better tolerance by the patients, a single nasopharyngeal swab has become the specimen of choice. Wang et, al., in their recent study have reported that oropharyngeal swabs (n=398) were used much more frequently than nasal swabs (n=8) in China during the COVID-19 outbreak; however, they were able to detect SARS-CoV-2 RNA in only 32% of oropharyngeal swabs, which was significantly lower than the level in nasal swabs (63%) 14 . In order to increase the sensitivity, the WHO recommends the collection of a combined nasopharyngeal and oropharyngeal swab 15 . However, an important aspect to consider while collecting both nasal and oral swabs either as independent specimens or together within a single aliquot of viral transport medium is that it may place potential stress on national and institutional supply chains. Once collected, swabs should be placed in vials containing Viral Transport Medium (VTM) and transported to the laboratory within 24-72 hours, ideally under refrigerated conditions (4-8 °C). If delays in transport are expected, the samples should be stored at -70 °C. Lower respiratory tract specimens such as sputum and bronchoalveolar lavage are used for late detection and monitoring of patients with severe COVID-19 pneumonia 6, 16 . A recent study concluded that bronchoalveolar lavages yield the highest SARS-CoV-2 RNA 14 . It should however be noted that this study did not compare/evaluate the use of nasopharyngeal or oropharyngeal swabs. In patients J o u r n a l P r e -p r o o f requiring emergent intubation, a lower respiratory tract specimen should be collected during the intubation procedure. Some patients with COVID-19 pneumonia have also demonstrated high viral loads in fecal material late in their clinical course 17 . The enteric involvement in patients with severe coronavirus infections has previously been established where SARS coronaviruses were isolated from the stool and were also demonstrated in enterocytes under the electron microscope 18, 19 . Thus, in addition to direct respiratory samples, in advanced COVID-19 cases, rectal swabs may be preferred sample for diagnosis 18 . Since its emergence the development of SARC-CoV-2 diagnostics has advanced rapidly. While most countries are relying on nucleic acid testing, there is an ongoing effort to develop serological tests 20, 21 . Immunoassays have been developed for the rapid detection of SARS-CoV-2 antigens or antibodies. Deep sequencing molecular methods such as the next-generation sequencing and metagenomic nextgeneration sequencing will play an important role in determining future SARS-CoV-2 mutation but are currently of no use in the diagnosis of COVID-19. Cases of SARS-CoV-2 tested negative for endemic HCoVs included in the molecular repository panels 9 . Thereby indicating the need for different sets of target oligonucleotides. Eleven molecular devices for diagnosis of SARS-CoV-2 had received urgent approval from National Medical Products Administration (NMPA) during the growing outbreak in China. Variable performance has been reported on these devices [25] [26] [27] [28] . It is however important to note that nine out of these eleven devices incorporated real-time RT-PCR techniques with hydrolysis probes. Since then most of the molecular diagnostics being developed for the diagnosis of COVID-19 infections involve real-time RT-PCR. A major advantage of real-time RTPCR assays is that amplification and analysis are done simultaneously in a closed system to minimize false-positive results associated with amplification product contamination. Several RTPCR protocols for detection of SARSCoV-2 RNA have been posted by J o u r n a l P r e -p r o o f Amplification (LAMP), and multiplex isothermal amplification followed by microarray 32 . Coronaviruses have a number of molecular targets within their positive-sense, single-stranded RNA genome that can be used for PCR assays 11, 13 . These include structural proteins, including envelope glycoproteins spike (S), envelope (E), transmembrane (M), helicase (Hel), and nucleocapsid (N). In addition to these genes that encode structural proteins, there are species-specific accessory genes that are required for viral replication. These include RNA dependent RNA polymerase (RdRp), hemagglutininesterase (HE), and open reading frames 136 ORF1a and ORF1b 1, 9 . To avoid possible cross-reaction with other endemic coronaviruses, at least two molecular targets should be included in the assay for detection of SARS-CoV-2. The ideal design would include at least one conserved region and one specific region to mitigate against the effects of genetic drift, especially as the virus evolves within new populations. The CDC recommends two nucleocapsid targets (N1 and N2) while WHO recommends initial screening with E gene followed by confirmation using the RdRp 1 . Origin and evolution of pathogenic coronaviruses Worldwide reduction in MERS cases and deaths since 2016 The aetiology, origins, and diagnosis of severe acute respiratory syndrome Coronavirus disease (COVID-19) outbreak-available at Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding World Health Organization Virological assessment of hospitalized patients with COVID-2019 Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by realtime reverse transcription-PCR assays Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Detection of SARS-CoV-2 in Different Types of Clinical Specimens World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) In suspected human cases Quantitative Detection and Viral Load Analysis of SARS -CoV-2 in Infected Patients Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in 235 Singapore Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase World Health Organization. Coronavirus disease (COVID-19) technical guidance: 251 laboratory testing for 2019-nCoV in humans Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): CDC 255 tests for COVID-19. Last reviewed March 9 Differentiation between human coronaviruses NL63 and 229E using a novel double antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies Molecular diagnosis of severe acute respiratory syndrome: the state of the art Emerging molecular assays for detection and characterization of respiratory viruses Multicenter evaluation of the ePlex respiratory pathogen panel for the detection of viral and bacterial respiratory tract pathogens in nasopharyngeal swabs Comparison of the Luminex xTAG RVP fast assay and the IdahoTechnology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital Novel Coronavirus in the United States Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany